Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New York for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New York only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New York (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Armistead Williams (NPI 1073580908)

Field	Value
Entity Type	Individual
Organization	Armistead Williams
Address	521 W 57th St
City	New York
State	NY
ZIP	10019
Taxonomy	Neurology Physician
NPI Enumerated	February 28, 2006

Payer Source	Total Paid
Medicare	$6.7M
Medicaid	$0

Key Findings

The provider’s code mix is dominated by high-cost biologic infusions consistent with a neurology practice treating multiple sclerosis and other immune-mediated neurologic conditions: J2350 (ocrelizumab), J2323 (natalizumab), J1561 (immune globulin), and J9312 (rituximab) account for the bulk of drug-related activity. The presence of these injectable biologics and immunomodulatory agents alongside infusion administration codes indicates the operation functions as an infusion-centric neurology practice rather than a primarily diagnostic-only clinic.

Revenue is heavily concentrated in a very small number of items: top 3 Medicare codes by revenue account for 90.9% of this provider's total Medicare revenue, with J2350 generating $4.6M (68.5%), J2323 $939.6K (13.9%), and J1561 $571.5K (8.4%) of the $6.7M total Medicare revenue. That level of concentration means most of the practice’s Medicare dollars are driven by a handful of biologic/injectable therapies.

This profile is effectively single-payer on file — total Medicare revenue is $6.7M while there is none below for Medicaid (no Medicaid billing on file) — so Medicare comprises the entire public-claims footprint shown. Reliance on Medicare-only revenue magnifies exposure to Medicare reimbursement and utilization changes for the specific drugs and infusion services the provider delivers.

For competitive standing the provider is a national outlier on J2350: 100.8K claims and $4.6M revenue, ranking #1 of 105 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code). That single-code dominance contrasts with more modest national positions on other top drugs and suggests this provider is a market leader for ocrelizumab administration.

Operational capacity for infusion is further supported by unusually high utilization of infusion administration codes: 96415 has 732 claims and $18.3K revenue (rank #26 of 4959 providers nationally, 99th percentile; extreme outlier), 96366 has 634 claims and $11.4K revenue (rank #118 of 2976, 96th percentile; notably above typical), and 96365 has 321 claims and $18.3K revenue (rank #871 of 8873, 90th percentile). These add-on and hourly infusion codes indicate substantial infusion throughput and support the inference of a dedicated infusion service line.

The practice also shows significant provision of high-complexity office care and specialized diagnostic procedures: 99215 appears with 255 claims and $37K revenue (rank #7863 of 145531, 95th percentile; notably above typical), and 62270 (a CSF/diagnostic procedure) shows 72 claims and $8.1K revenue (rank #4 of 140, 97th percentile). This mix implies ongoing, complex neurologic management—both drug administration and higher-acuity evaluation/diagnostics—rather than only episodic drug dispensing.

Outside of the J2350 dominance, volumes for the other top drugs are elevated but more typical: J2323 is 52.2K claims and $939.6K revenue (rank #6 of 40, 87th percentile; typical, unremarkable volume) and J1561 is 15K claims and $571.5K revenue (rank #19 of 180, 90th percentile; typical, unremarkable volume). That pattern suggests a practice anchored by one flagship biologic service line supplemented by a broader infusion portfolio rather than uniformly extreme volumes across all drugs.

The provider has long tenure in public claims data, with NPI enumerated 2006-02-28 (~20 years ago), which supports the view of an established specialty infusion practice that has scaled over time. Analysts should consider that long-standing referral relationships and invested infusion capacity likely contribute to the concentrated, high-volume billing pattern observed, particularly for J2350.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

21 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2350	Injection, ocrelizumab, 1 mg	100,800	$50	$4.6M
J2323	Injection, natalizumab, 1 mg	52,200	$20	$939.6K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	15,040	$40	$571.5K
J9312	Injection, rituximab, 10 mg	6,800	$60	$428.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	320	$120	$37K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	260	$150	$37K
J0475	Injection, baclofen, 10 mg	260	$140	$35.8K
96415	In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the…	730	$30	$18.3K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	320	$60	$18.3K
96366	The provider administers an intravenous infusion or infusions of a medication for an additional hour or subsequent hours after the first hour to prevent, treat, or diagnose a condition or disease.	630	$20	$11.4K

Showing 1–10 of 21

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New York Distribution

Armistead Williams — 5 of 21 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New York

Full comparison — all codes billed, vs. state median

21 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2350	1	10	14,700	$50	$1.4M
J2323	2	10	33,000	$20	$632.8K
J1561	4	40	3,100	$40	$234.9K
J9312	1	20	2,550	$60	$175K
J0475	5	10	280	$140	$50.2K
96413	47	380	110	$110	$18.1K
99215	406	8,280	40	$140	$10.1K
96365	60	610	80	$60	$7.7K
99205	2,708	4,260	30	$180	$6.4K
62370	5	30	60	$70	$5.5K

Showing 1–10 of 21

Related Providers

Other providers that share a Tax Identification Number (TIN) with Armistead Williams, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
James Stark	NY	Neurology Physician	$827.7K	$0

Nearby Providers

Other providers in the same ZIP code as Armistead Williams, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
St Lukes Roosevelt Hospital Center	NY	General Acute Care Hospital	$0	$190.5M
Karen Thornton	NY	Family Medicine Physician	$183K	$13.5M
West Side Gi, LLC	NY	Ambulatory Surgical Clinic/Center	$566.4K	$13M
Roosevelt Surgery Center, LLC	NY	Ambulatory Surgical Clinic/Center	$1.1M	$938.4K
Elizabeth Kavaler	NY	Urology Physician	$1.7M	$0
Esoterix Genetic Laboratories, LLC	NY	Clinical Medical Laboratory	$418.7K	$724.2K
Suelane Do Ouro	NY	Interventional Pain Medicine Physician	$682.3K	$332.8K
Robert Howard	NY	Registered Dietitian	$17K	$962.8K
Alexander Volvovsky	NY	Diagnostic Radiology Physician	$814.1K	$0
Stephen Manghisi	NY	Diagnostic Radiology Physician	$593.1K	$570

Armistead Williams — Billing Profile & Reimbursement Data

Sign up for Armistead Williams — Billing Profile & Reimbursement Data policy alerts

Armistead Williams — Billing Profile & Reimbursement Data

Sign up for Armistead Williams — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References